These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24919833)

  • 1. We need to talk about depot: effect of Community Treatment Order on depot antipsychotic medication compliance.
    Suetani S; Foo E; Wilson D
    Australas Psychiatry; 2014 Aug; 22(4):357-359. PubMed ID: 24919833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance with depot antipsychotic medication by patients attending outpatient clinics.
    Heyscue BE; Levin GM; Merrick JP
    Psychiatr Serv; 1998 Sep; 49(9):1232-4. PubMed ID: 9735970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
    Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
    Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.
    Jaeger M; Rossler W
    Psychiatry Res; 2010 Jan; 175(1-2):58-62. PubMed ID: 20004980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community.
    Kasinathan J; Sharp G; Barker A
    Ther Adv Psychopharmacol; 2016 Oct; 6(5):301-307. PubMed ID: 27721969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician.
    Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B
    Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The subjective experiences of people who regularly receive depot neuroleptic medication in the community.
    Phillips L; McCann E
    J Psychiatr Ment Health Nurs; 2007 Sep; 14(6):578-86. PubMed ID: 17718731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
    Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
    Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing issues and depot medication in the maintenance treatment of schizophrenia.
    Kane JM
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():65-71. PubMed ID: 8866767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of depot medication in the long-term-treatment of schizophrenia].
    Kühn KU; Wiedemann K; Hellweg R; Möller HJ
    Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
    Patel MX; De Zoysa N; Bernadt M; David A
    J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial compliance with antipsychotic medication is common in patients with schizophrenia.
    Rummel-Kluge C; Schuster T; Peters S; Kissling W
    Aust N Z J Psychiatry; 2008 May; 42(5):382-8. PubMed ID: 18473256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.